InsiderTrades

Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD

Accepted 2026-09-22 17:01:52 ET · period of report 2026-09-18 · accession 0001193125-26-398105 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-09-22 17:01 2026-09-18 TEVA Savage Brian Interim CLO M - OptEx $34.70 +4,503 15.8K +40% +$156.3K
DM 2026-09-22 17:01 2026-09-18 TEVA Savage Brian Interim CLO S - Sale+OE $38.85 -7,342 8,500 -46% -$285.2K
D 2026-09-22 17:01 2026-09-18 TEVA Savage Brian Interim CLO M - OptEx $34.70 -4,503 0 -100% -$156.3K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Ordinary Shares 2026-09-18 M A 4,503 $34.70 15,842 D — —
2 Common Ordinary Shares 2026-09-18 S D 4,503 $38.69 11,339 D — —
3 Common Ordinary Shares 2026-09-18 S D 2,525 $39.15 8,814 D — — (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.14 to $39.155, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
4 Common Ordinary Shares 2026-09-18 S D 314 $38.70 8,500 D — —
5 Derivative Stock Options (right to buy) 2026-09-18 M D 4,503 $34.70 0 D $34.70 · — to 2027-03-03 4,503 Ordinary Shares (F2) Stock options were granted on March 3, 2017, with 1,125 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 1,128 vested on March 3, 2021.